The present review discusses ABC transporters which have been suggested to promote lowering of cerebral Aβ, changes in their expression and/or activity in AD brain, experimental approaches which have been used to increase their expression, and findings in clinical trials which have explored the effects of these approaches in patients with AD or mild cognitive impairment (MCI). Here, ABCG2 is linked to Alzheimer disease.